Equity - RSUs and Performance Shares (Details) $ / shares in Units, $ in Millions		12 Months Ended
		Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($)	May 08, 2020 shares
Allergan plc
Weighted-average grant date fair value
Granted in acquisition (in shares)	[1]				8,200,000
RSUs | Minimum vesting period
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
RSUs | Maximum vesting period
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Performance-vested RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incremental vesting		0.33
Performance period		3 years
Common stock received for each vested award (in shares)		1
Performance shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incremental vesting		0.33
Performance period		3 years
RSUs and performance shares
Share units
Shares units outstanding at the beginning of the period (in shares)		15,918,000
Granted (in shares)		7,556,000
Vested (in shares)		(6,735,000)
Forfeited (in shares)		(1,849,000)
Shares units outstanding at the end of the period (in shares)		14,890,000	15,918,000
Weighted-average grant date fair value
Weighted average fair value outstanding at the beginning of the period (in dollars per share) | $ / shares		$ 87.03
Granted (in dollars per share) | $ / shares		105.79
Vested (in dollars per share) | $ / shares		91.63
Forfeited (in dollars per share) | $ / shares		83.35
Weighted average fair value outstanding at the end of the period (in dollars per share) | $ / shares		$ 94.93	$ 87.03
Fair market value of awards vested | $		$ 718	$ 618	$ 371
Unrecognized compensation cost | $		$ 592
Period for recognition of unrecognized compensation cost		2 years

[1] Represents the pre-acquisition service portion of the fair value of 11 million AbbVie stock options and 8 million RSUs issued to Allergan equity award holders.